WANA (Nov 23) – The domestic production of an advanced nano-medicine—one of the most cutting-edge targeted cancer therapies—has brought significant foreign-currency savings, reduced treatment costs, and improved patient care in Iran during 2024.
This nano-drug, designed for patients with HER2-positive breast cancer, is produced using the highly sophisticated Antibody–Drug Conjugate (ADC) technology. Its performance is based on nanoscale targeting of tumor cells. According to official information, the drug has received approval from the Food and Drug Administration and has been granted an export license. It is now produced on an industrial scale and fully meets domestic demand without reliance on imports.
The annual market size of the drug is estimated at over 200,000 vials. If supplied locally, this capacity significantly reduces Iran’s dependence on importing one of the world’s most expensive cancer medicines.
WANA (Nov 20) – At the 24th National Congress of Medical Oncology and Hematology in Iran, Ardeshir Ghavami-Zadeh, Secretary of the Congress, announced that the survival rate of cancer patients in Iran has reached 70% over the past 20 years, attributing this improvement to advances in early screening and timely diagnosis. Ghavami-Zadeh highlighted lifestyle […]
One of the key advantages of Tedrox is its remarkable price difference compared with the foreign version. The domestic price is 22 million tomans (around USD 200) per vial, while the imported equivalent costs USD 3,036—more than 15 times higher. This price gap not only eases the financial burden on families but also leads to tens of millions of dollars in foreign-currency savings. In 2024 alone, estimates show that using the domestically produced drug saved Iran around $120 million, including reduced treatment-related and logistical costs—highlighting the strategic value of local, technology-driven production.
According to available data, this drug not only replaces imports but also has several million dollars in export potential, enabling Iran to increase its presence in the global market for targeted therapies. ADC technology—combining a specific antibody with an active drug—is among the world’s most complex pharmaceutical technologies, and Iran’s entry into this field marks a significant technological leap.
Citing the Nanotechnology Headquarters, beyond cost savings and reduced treatment expenses, this medicine has a direct impact on improving the quality of life of cancer patients, offering stable access, consistent treatment, reduced psychological and financial pressure on families, and greater hope for recovery.
